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TRPA1

:   transient receptor potential ankyrin‐1

ALSPAC

:   Avon Longitudinal Study of Parents and Children

PIAMA

:   Prevention and Incidence of Asthma and Mite Allergy

SNP

:   single nucleotide polymorphism

PAF

:   population attributable fraction

LD

:   linkage disequilibrium

Introduction {#pai12673-sec-0005}
============

The transient receptor potential ankyrin‐1 (TRPA1) ion channel is expressed on peripheral endings of primary afferent neurons and is a highly conserved sensor of noxious reactive electrophiles; these form covalent adducts with the receptor to activate the neurons [1](#pai12673-bib-0001){ref-type="ref"}. In particular, TRPA1 is a major oxidant sensor in the airways [2](#pai12673-bib-0002){ref-type="ref"}, sensing exogenous airborne irritants as well as endogenous by‐products of oxidative stress [3](#pai12673-bib-0003){ref-type="ref"}. In keeping with this function, the TRPA1 receptor is thought to play a key role in the cough reflex [4](#pai12673-bib-0004){ref-type="ref"} and in promoting airway inflammation in asthma [3](#pai12673-bib-0003){ref-type="ref"}, [5](#pai12673-bib-0005){ref-type="ref"}. Experiments using knockout mice and TRPA1 antagonists have shown that TRPA1 plays a critical role in allergic and non‐allergic neurogenic airway inflammation and hyper‐reactivity [6](#pai12673-bib-0006){ref-type="ref"}, [7](#pai12673-bib-0007){ref-type="ref"}. However, evidence implicating TRPA1 in asthma in humans is lacking.

Following our initial discovery of an association between frequent paracetamol (acetaminophen) use and asthma in adults [8](#pai12673-bib-0008){ref-type="ref"}, we and others have reported that maternal use of paracetamol in pregnancy was associated with an increased risk of childhood asthma, wheezing and elevated total IgE concentration [9](#pai12673-bib-0009){ref-type="ref"}. Nassini et al. [10](#pai12673-bib-0010){ref-type="ref"} subsequently showed in a rodent model that systemic administration of therapeutic doses of paracetamol led to generation of its electrophilic and reactive metabolite in the lung which, in turn, caused neurogenic airway inflammation through activation of TRPA1; they proposed that this mechanism might explain the epidemiological link between paracetamol exposure and asthma in humans.

In a population‐based birth cohort, we investigated whether *TRPA1* (8q13) gene variants are associated with childhood asthma and IgE concentration, and whether these associations were modified by prenatal exposure to paracetamol. We also sought to obtain confirmatory evidence for the most significant SNP associations in the Prevention and Incidence of Asthma and Mite allergy (PIAMA) and Generation R birth cohorts.

Methods {#pai12673-sec-0006}
=======

Avon Longitudinal Study of Parents and Children {#pai12673-sec-0007}
-----------------------------------------------

### Subjects {#pai12673-sec-0008}

The Avon Longitudinal Study of Parents and Children (ALSPAC) is a population‐based birth cohort that recruited 14,541 predominantly white pregnant women resident in Avon, UK, with expected dates of delivery 1st April 1991--31st December 1992. Of these pregnancies, there were 14,062 live births and 13,988 children alive at 1 year of age. The cohort has been followed since birth with annual questionnaires and, since age 7 years, with objective measures in research clinics. The study protocol has been described previously [11](#pai12673-bib-0011){ref-type="ref"}, [12](#pai12673-bib-0012){ref-type="ref"} (further information at: <http://www.alspac.bris.ac.uk>). Ethics approval was obtained from the ALSPAC Ethics and Law Committee (IRB 00003312) and the Local Research Ethics Committees.

### Outcomes {#pai12673-sec-0009}

When the children were 7.5 years old, mothers were asked: 'Has your child had any of the following in the past 12 months: wheezing; asthma?' Children were defined as having current doctor‐diagnosed asthma (primary outcome) if mothers responded positively to the question 'Has a doctor ever actually said that your study child has asthma?' and positively to one or both of the questions on wheezing and asthma in the past 12 months.

Serum total IgE concentration (kU/l) was measured by fluoroimmunoassay using the Pharmacia UNICAP system (Pharmacia & Upjohn Diagnostics AB, Uppsala, Sweden) at 7 years.

### Prenatal paracetamol exposure {#pai12673-sec-0010}

Mothers were asked at 18--20 weeks how often they had taken paracetamol ('not at all, sometimes, most days, every day') during their pregnancy. At 32 weeks, they were asked the same question about use in the previous 3 months. Hence, we defined use of paracetamol (Yes/No) in early (\<18--20 weeks) and late (20--32 weeks) pregnancy.

### Genotyping and selection of *TRPA1* SNPs {#pai12673-sec-0011}

DNA samples were extracted from lymphoblastoid cell lines, cord blood or venous blood collected at 7 years of age, with a small number extracted from venous blood collected at 43--61 months. A total of 9912 subjects were genotyped at 500,527 SNPs using the Illumina HumanHap550 quad genomewide SNP genotyping platform. After applying rigorous exclusion criteria, genotype data were available for 8365 unrelated individuals (see Online Supplement for further details).

We identified 29 SNPs in *TRPA1* (8q13) which had been included in a genetic association study of cough [13](#pai12673-bib-0013){ref-type="ref"}. The participating cohorts in that study were part of a large European GWAS of asthma (the GABRIEL consortium) [14](#pai12673-bib-0014){ref-type="ref"}. All SNPs within the gene region had been selected, allowing capture of the majority of common haplotype variations of the gene [13](#pai12673-bib-0013){ref-type="ref"}, [14](#pai12673-bib-0014){ref-type="ref"}. In addition, we identified 11 SNPs (four of which had already been selected) associated with various pain phenotypes [15](#pai12673-bib-0015){ref-type="ref"}, [16](#pai12673-bib-0016){ref-type="ref"}, [17](#pai12673-bib-0017){ref-type="ref"} and with menthol preference in smokers [18](#pai12673-bib-0018){ref-type="ref"}. Of the 36 potential SNPs, five had not been typed or could not be imputed, leaving 31 SNPs to be analysed. Of these SNPs, 21 were genotyped and 10 were imputed. Where genotyped data were missing, these were replaced by imputed data if possible (see Online Table S1 and Supplement for further details).

### Statistical analysis of ALSPAC data {#pai12673-sec-0012}

Although the GWAS data set only included individuals of European ancestry, we excluded mother--child pairs from all analyses if the mother\'s reported ethnicity was non‐white or unknown (14.1% of the cohort) to further reduce potential confounding by population substructure. We used logistic regression to analyse relations of child *TRPA1* genotype with asthma, and linear regression to analyse associations with log‐transformed total IgE concentration. All analyses were carried out using Stata (version 10.1). Univariate gene main effects were evaluated as continuous per‐allele effects and using between genotype comparisons. We used Haploview [19](#pai12673-bib-0019){ref-type="ref"} to compute linkage disequilibrium (LD) statistics for the 31 *TRPA1* SNPs of interest. The population attributable fraction (PAF) was calculated using the formula: PAF = 1‐PUF, where PUF is the population unattributable fraction [20](#pai12673-bib-0020){ref-type="ref"}. We used the Nyholt approach [21](#pai12673-bib-0021){ref-type="ref"} updated by Li and Ji [22](#pai12673-bib-0022){ref-type="ref"} to estimate the effective number of independent marker loci in our data (12.8 of 31) and the threshold required to keep type I error rate at 5% after adjusting for multiple testing (p value=0.05/12.8 = 0.004).

PIAMA and Generation R (Netherlands) {#pai12673-sec-0013}
------------------------------------

The Prevention and Incidence of Asthma and Mite Allergy (PIAMA) birth cohort is a multicentre study that selected 4146 pregnant women in the Netherlands in 1996/1997 [23](#pai12673-bib-0023){ref-type="ref"}, [24](#pai12673-bib-0024){ref-type="ref"}. The Generation R Study is a population‐based prospective cohort study of pregnant women and their children in Rotterdam [25](#pai12673-bib-0025){ref-type="ref"}, [26](#pai12673-bib-0026){ref-type="ref"}. All children were born between April 2002 and January 2006, and currently followed until young adulthood. Current doctor‐diagnosed asthma at 8 years and at 6 years was defined in PIAMA and Generation R, respectively (see Online Supplement for further details).

We analysed the associations between *TRPA1* (for SNPs most significantly associated with asthma in ALSPAC) and asthma separately in PIAMA and Generation R, and then undertook a meta‐analysis across the three cohorts, using a fixed‐effects model.

Other European asthma studies {#pai12673-sec-0014}
-----------------------------

In other European studies included in the GABRIEL study [14](#pai12673-bib-0014){ref-type="ref"}, we explored associations between doctor‐diagnosed asthma 'ever' (of childhood‐onset) and the *TRPA1* SNPs most significantly associated with asthma in ALSPAC. We carried out these subsidiary analyses using publicly available data from GABRIEL and meta‐analysed the data using a fixed‐effects model.

Results {#pai12673-sec-0015}
=======

In ALSPAC, information on current doctor‐diagnosed asthma at age 7.5 years was obtained for 7221 children. After excluding non‐white mother--child pairs, and applying quality criteria to imputed genotype data, *TRPA1* genotype data were available for 6901 children, generating a final sample of 5141 white children with complete data on asthma and genotype, of whom 614 (11.9%) children had current doctor‐diagnosed asthma at age 7.5 years. A total of 53.9% and 42.3% of children were exposed to paracetamol *in utero* during early and late pregnancy, respectively. Data on total IgE concentration and genotype were available for 3834 children.

*TRPA1* genotype data are summarized in Table S1. *TRPA1* genotype frequencies did not deviate from Hardy--Weinberg equilibrium for the 31 SNPs of interest (p \> 0.05). In PIAMA, information on current doctor‐diagnosed asthma at age 8 years was obtained for 3253 children, and *TRPA1* genotype data were available for 1968 children, generating a final sample of 1877 white children with data on asthma and genotype, of whom 89 (4.7%) had current doctor‐diagnosed asthma at age 8 years. In Generation R, data on *TRPA1* genotype and current doctor‐diagnosed asthma at age 6 years were available for 2073 children, after excluding twins and restricting to Caucasians only, based on genetic ancestry. Of these, 64 children (3.1%) had current doctor‐diagnosed asthma.

Gene main effects in ALSPAC {#pai12673-sec-0016}
---------------------------

Table [1](#pai12673-tbl-0001){ref-type="table-wrap"} shows the per‐allele associations between *TRPA1* genotypes and asthma in ALSPAC. Of the 31 SNPs tested, 13 were associated with asthma (p \< 0.05). The six SNPs (five genotyped, one imputed) that were most significantly associated with asthma (p \< 0.005) were as follows: rs959974 and rs1384001 (per‐allele odds ratio for both SNPs: 1.30 (95% CI: 1.15--1.47), p = 0.00001), rs7010969 (OR 1.28 (1.13--1.46), p = 0.00004), rs3735945 (OR 1.30 (1.09--1.55), p = 0.003), rs920829 (OR 1.30 (1.09--1.54), p = 0.004) and rs4738202 (OR 1.22 (1.07--1.39), p = 0.004). Adjustment for multiple testing suggested that associations with these six SNPs (and especially the first four) were unlikely to have arisen by chance (adjusted p value threshold 0.004). With a more rigorous p value threshold of 0.001, evidence against the null hypothesis was still very strong for 3 SNPs.

###### 

Per‐allele associations between child *TRPA1* SNPs and current doctor‐diagnosed asthma at 7.5 years in ALSPAC

  SNP          Position   Doctor‐diagnosed asthma at 7 years                       
  ------------ ---------- ------------------------------------ ------------------- ---------
  rs12540984   72927920   5110                                 1.00 (0.84--1.18)   0.985
  rs4738201    72930711   5140                                 1.16 (1.03--1.31)   0.013
  rs6996723    72933632   5141                                 0.88 (0.75--1.04)   0.137
  rs7827617    72934032   5141                                 1.21 (1.04--1.41)   0.013
  rs959974     72935839   5141                                 1.30 (1.15--1.47)   0.00001
  rs959976     72936145   5141                                 1.22 (1.05--1.42)   0.008
  rs1384001    72936237   5141                                 1.30 (1.15--1.47)   0.00001
  rs13279503   72939626   5116                                 1.08 (0.95--1.22)   0.222
  rs4738202    72940861   5141                                 1.22 (1.07--1.39)   0.004
  rs13280644   72948588   5141                                 0.82 (0.66--1.02)   0.075
  rs13249568   72949209   5141                                 0.95 (0.83--1.09)   0.468
  rs10504523   72951490   5141                                 0.95 (0.83--1.09)   0.484
  rs1025926    72953158   5141                                 1.14 (1.00--1.30)   0.055
  rs10504524   72955891   5141                                 0.95 (0.83--1.09)   0.479
  rs13255063   72959535   5140                                 0.95 (0.83--1.09)   0.476
  rs1025927    72963135   5138                                 0.82 (0.66--1.01)   0.067
  rs1025928    72963258   5141                                 0.94 (0.83--1.07)   0.344
  rs10504525   72965123   5141                                 1.06 (0.90--1.25)   0.494
  rs3735942    72965973   5141                                 1.11 (0.98--1.26)   0.097
  rs3735943    72966002   5141                                 0.88 (0.78--0.99)   0.040
  rs10504526   72966552   5141                                 1.13 (1.01--1.28)   0.041
  rs12548486   72971527   5138                                 1.11 (0.98--1.26)   0.102
  rs10109581   72974329   5141                                 1.19 (1.05--1.36)   0.009
  rs3735945    72974806   5141                                 1.30 (1.09--1.55)   0.003
  rs920829     72977703   5136                                 1.30 (1.09--1.54)   0.004
  rs1443952    72980652   5141                                 1.11 (0.98--1.25)   0.116
  rs7010969    72982365   5141                                 1.28 (1.13--1.46)   0.00004
  rs7011431    72982398   5141                                 1.20 (1.05--1.36)   0.008
  rs4738206    72986348   5141                                 1.10 (0.97--1.25)   0.120
  rs2278655    72987277   5038                                 1.01 (0.79--1.28)   0.964
  rs13268757   72987638   5097                                 1.06 (0.89--1.25)   0.528
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Additional effect estimates using between genotype comparisons for these six SNPs in relation to asthma are shown in Table [2](#pai12673-tbl-0002){ref-type="table-wrap"}. This shows that, for four of these SNPs, children who were homozygous for the risk allele were approximately 70% more likely to have asthma than children who were homozygous for the non‐risk allele. Of the 31 SNPs tested, only three (rs959974, rs1384001, rs4738202) were nominally associated with total IgE concentration (p \< 0.05) (Table S2).

###### 

Associations between the six most significantly associated *TRPA1* SNPs in ALSPAC and current doctor‐diagnosed asthma at 7--8 years in ALSPAC and PIAMA, and current doctor‐diagnosed asthma at 6 years in Generation R

  SNP                                                Alleles   ALSPAC              PIAMA     GENERATION R                                                                                                                                                
  -------------------------------------------------- --------- ------------------- --------- -------------- ---------------------------------------------------------- ------- ------- ---------------------------------------------------------- ------ --
  rs959974[a](#pai12673-note-0002){ref-type="fn"}    G/G       1401                1.00                     512                                                        1.00            555                                                        1.00   
  G/T                                                2615      1.33 (1.07--1.65)   0.009     932            1.36 (0.77--2.38)                                          0.28    1054    1.15 (0.61, 2.14)                                          0.67   
  T/T                                                1125      1.69 (1.32--2.16)   0.00001   433            1.82 (0.99--3.36)                                          0.053   464     1.39 (0.68, 2.82)                                          0.37   
  Per allele                                                   1.30 (1.15--1.47)   0.00001                  1.35 (1.00--1.83)                                          0.052           1.18 (0.83, 1.68)                                          0.37   
  rs1384001[b](#pai12673-note-0003){ref-type="fn"}   C/C       1400                1.00                     512                                                        1.00            555                                                        1.00   
  A/C                                                2616      1.33 (1.07--1.65)   0.009     933            1.36 (0.78--2.38)                                          0.28    1054    1.15 (0.61, 2.14)                                          0.67   
  A/A                                                1125      1.69 (1.32--2.15)   0.00001   432            1.83 (0.99--3.37)                                          0.053   464     1.39 (0.68, 2.82)                                          0.37   
  Per allele                                                   1.30 (1.15--1.47)   0.00001                  1.35 (1.00--1.83)                                          0.051           1.18 (0.83, 1.68)                                          0.37   
  rs4738202[a](#pai12673-note-0002){ref-type="fn"}   A/A       483                 1.00                     150                                                        1.00            179                                                        1.00   
  A/G                                                2233      1.45 (1.02--2.05)   0.038     816            1.54 (0.54--4.41)                                          0.42    880     0.71 (0.30, 1.68)                                          0.44   
  G/G                                                2425      1.66 (1.18--2.34)   0.004     911            2.21 (0.79--6.20)                                          0.13    1,014   0.78 (0.34, 1.81)                                          0.57   
  Per allele                                                   1.22 (1.07--1.39)   0.004                    1.45 (1.01--2.09)                                          0.042           0.96 (0.65, 1.41)                                          0.83   
  rs7010969[b](#pai12673-note-0003){ref-type="fn"}   A/A       827                 1.00                     299                                                        1.00            324                                                        1.00   
  A/C                                                2477      1.43 (1.09--1.89)   0.010     920            1.09 (0.56--2.10)                                          0.80    1005    1.08 (0.51, 2.32)                                          0.84   
  C/C                                                1837      1.74 (1.31--2.29)   0.00005   658            1.42 (0.73--2.77)                                          0.30    744     1.20 (0.55, 2.62)                                          0.65   
  Per allele                                                   1.28 (1.13--1.46    0.00004                  1.23 (0.89--1.68)                                          0.21            1.10 (0.76, 1.59)                                          0.61   
  rs3735945[b](#pai12673-note-0003){ref-type="fn"}   C/C       4067                1.00                     1519                                                       1.00            1621                                                       1.00   
  C/T                                                1005      1.38 (1.13--1.68)   0.002     338            1.15 (0.67--1.95)                                          0.61    428     1.40 (0.80, 2.47)                                          0.24   
  T/T                                                69        1.19 (0.59--2.41)   0.633     20             0.00 (0.00 to --)[c](#pai12673-note-0004){ref-type="fn"}   0.99    24      0.00 (0.00 to --)[c](#pai12673-note-0004){ref-type="fn"}   0.99   
  Per allele                                                   1.30 (1.09--1.55)   0.003                    1.01 (0.61--1.65)                                          0.98            1.21 (0.71, 2.04)                                          0.48   
  rs920829[d](#pai12673-note-0005){ref-type="fn"}    C/C       4066                1.00                     1519                                                       1.00            1621                                                       1.00   
  C/T                                                1001      1.37 (1.12--1.68)   0.002     338            1.15 (0.67--1.95)                                          0.61    428     1.40 (0.80, 2.47)                                          0.24   
  T/T                                                69        1.19 (059--2.41)    0.634     20             0.00 (0.00 to --)[c](#pai12673-note-0004){ref-type="fn"}   0.99    24      0.00 (0.00 to --)[c](#pai12673-note-0004){ref-type="fn"}   0.99   
  Per allele                                                   1.30 (1.09--1.54)   0.004                    1.01 (0.61--1.65)                                          0.98            1.21 (0.71, 2.04)                                          0.48   

Genotyped in ALSPAC and in PIAMA, and imputed in Generation R.

Genotyped in ALSPAC, and imputed in PIAMA and Generation R.

No asthma cases in minor allele homozygote group in PIAMA and Generation R.

Imputed in ALSPAC and in PIAMA, and genotyped in Generation R.
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Fig. S1 in the online supplement shows LD (r^2^) between the 31 *TRPA1* SNPs; 29 of those SNPs are located in four LD blocks. Of the six SNPs most significantly associated with asthma, two (rs959974 and rs1384001) were in one block, rs4738202 was in another block, and rs7010969, rs3735945 and rs920829 were in a third block. We chose three of the most significantly associated SNPs from different LD blocks (rs959974, rs7010969 and rs4738202) to separately estimate the proportion of asthma in the population attributable to *TRPA1* genotype (PAF). The PAF estimates were, respectively, 21.7% (95% CI: 9.6--32.2; p = 0.001), 29.1% (12.5--42.6; p = 0.001) and 30.7% (7.7--47.9; p = 0.012).

Gene main effects in PIAMA and Generation R and meta‐analysis {#pai12673-sec-0017}
-------------------------------------------------------------

Table [2](#pai12673-tbl-0002){ref-type="table-wrap"} also shows the associations between the six SNPs most significantly associated with asthma in ALSPAC and asthma in the PIAMA and Generation R cohorts. In PIAMA, there was some evidence for association (p ≤ 0.05) with asthma for the three SNPs most significantly associated with asthma in ALSPAC, with effect estimates that were larger than those in ALSPAC. In Generation R, none of the six SNPs were associated with asthma. Fig. [1](#pai12673-fig-0001){ref-type="fig"} shows the Forest plots for the weighted per‐allele associations of the six SNPs with asthma. For all six SNPs, the pooled effect estimates confirmed significant associations with asthma.

![Forest plots showing meta‐analysis of the per‐allele associations between the six *TRPA1* SNPs most significantly associated with asthma in ALSPAC and current asthma in ALSPAC,PIAMA and Generation R.](PAI-28-191-g001){#pai12673-fig-0001}

Gene main effects in other European asthma studies {#pai12673-sec-0018}
--------------------------------------------------

Figs S2--S6 online show Forest plots for the meta‐analysis of the associations between *TRPA1* and childhood‐onset asthma across GABRIEL studies, for five of the six SNPs most significantly associated with asthma in ALSPAC (rs920829 was not genotyped in GABRIEL; it was imputed in ALSPAC, but it is in strong LD with rs3735945). The plots compare associations with current doctor‐diagnosed asthma in ALSPAC and PIAMA versus associations with doctor‐diagnosed asthma 'ever' (of childhood‐onset) across other GABRIEL studies, with three studies which were exclusively of children separated from remaining studies. The pooled effect estimates do not confirm associations with asthma 'ever'. Furthermore, there was evidence of substantial heterogeneity in the effect estimates for the three childhood GABRIEL studies.

Paracetamol analyses in ALSPAC {#pai12673-sec-0019}
------------------------------

For the 13 SNPs associated with asthma (p \< 0.05), we stratified the per‐allele associations by early and late gestation paracetamol exposure. Associations were similar in exposed and unexposed children for the six SNPs most significantly associated with asthma overall (Table [3](#pai12673-tbl-0003){ref-type="table-wrap"}) and for the remaining 7 SNPs (data not shown). For the three SNPs associated with IgE concentration (p \< 0.05), we similarly stratified the per‐allele associations by prenatal paracetamol exposure (Table [4](#pai12673-tbl-0004){ref-type="table-wrap"}). *TRPA1* was associated with IgE concentration amongst children who were exposed, especially in later gestation, but not amongst non‐exposed children (p‐interaction 0.02 for rs959974 and rs1384001, and 0.06 for rs4738202).

###### 

Per‐allele associations between the six most significantly associated *TRPA1* SNPs and current doctor‐diagnosed asthma, stratified by prenatal paracetamol exposure during early and late gestation in ALSPAC

  SNP         N      Paracetamol early in pregnancy OR (95% C.I.)   p‐value   N      Paracetamol later in pregnancy OR (95% C.I.)   p‐value
  ----------- ------ ---------------------------------------------- --------- ------ ---------------------------------------------- ---------
  rs959974                                                                                                                          
  Exposed     2734   1.29 (1.10--1.50)                              0.002     2118   1.26 (1.06--1.50)                              0.008
  Unexposed   2338   1.37 (1.12--1.66)                              0.002     2889   1.31 (1.10--1.56)                              0.002
                     p‐interaction                                  0.639            p‐interaction                                  0.765
  rs1384001                                                                                                                         
  Exposed     2734   1.29 (1.10--1.50)                              0.002     2118   1.26 (1.06--1.50)                              0.008
  Unexposed   2338   1.37 (1.12--1.66)                              0.002     2889   1.31 (1.10--1.56)                              0.002
                     p‐interaction                                  0.643            p‐interaction                                  0.760
  rs4738202                                                                                                                         
  Exposed     2734   1.22 (1.03--1.45)                              0.024     2118   1.23 (1.02--1.49)                              0.031
  Unexposed   2338   1.24 (1.00--1.54)                              0.049     2889   1.18 (0.97--1.43)                              0.090
                     p‐interaction                                  0.910            p‐interaction                                  0.753
  rs7010969                                                                                                                         
  Exposed     2734   1.25 (1.07--1.47)                              0.006     2118   1.25 (1.05--1.50)                              0.012
  Unexposed   2338   1.34 (1.09--1.64)                              0.005     2889   1.31 (1.09--1.57)                              0.003
                     p‐interaction                                  0.621            p‐interaction                                  0.738
  rs3735945                                                                                                                         
  Exposed     2734   1.15 (0.91--1.44)                              0.242     2118   1.31 (1.02--1.68)                              0.036
  Unexposed   2338   1.59 (1.20--2.09)                              0.001     2889   1.24 (0.96--1.60)                              0.096
                     p‐interaction                                  0.076            p‐interaction                                  0.755
  rs920829                                                                                                                          
  Exposed     2732   1.15 (0.91--1.44)                              0.238     2114   1.30 (1.01--1.67)                              0.041
  Unexposed   2335   1.57 (1.19--2.08)                              0.001     2888   1.24 (0.96--1.61)                              0.093
                     p‐interaction                                  0.086            p‐interaction                                  0.809
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###### 

Per‐allele associations between the three most significantly associated *TRPA1* SNPs and total IgE concentration, stratified by prenatal paracetamol exposure during early and late gestation in ALSPAC

  SNP         N      Paracetamol early in pregnancy GMR[a](#pai12673-note-0006){ref-type="fn"} (95% C.I.)   p‐value   N      Paracetamol later in pregnancy GMR[a](#pai12673-note-0006){ref-type="fn"} (95% C.I.)   p‐value
  ----------- ------ -------------------------------------------------------------------------------------- --------- ------ -------------------------------------------------------------------------------------- ---------
  rs959974                                                                                                                                                                                                          
  Exposed     2066   1.12 (1.01--1.24)                                                                      0.037     1587   1.22 (1.08--1.37)                                                                      0.001
  Unexposed   1719   1.05 (0.94--1.17)                                                                      0.408     2149   1.01 (0.91--1.12)                                                                      0.849
                     p‐interaction                                                                          0.414            p‐interaction                                                                          0.017
  rs1384001                                                                                                                                                                                                         
  Exposed     2066   1.12 (1.01--1.24)                                                                      0.037     1587   1.22 (1.08--1.37)                                                                      0.001
  Unexposed   1719   1.05 (0.94--1.17)                                                                      0.402     2149   1.01 (0.91--1.12)                                                                      0.849
                     p‐interaction                                                                          0.418            p‐interaction                                                                          0.016
  rs4738202                                                                                                                                                                                                         
  Exposed     2066   1.16 (1.03--1.29)                                                                      0.011     1587   1.21 (1.06--1.37)                                                                      0.003
  Unexposed   1719   1.02 (0.91--1.15)                                                                      0.714     2149   1.03 (0.92--1.15)                                                                      0.585
                     p‐interaction                                                                          0.145            p‐interaction                                                                          0.062

Geometric Mean Ratio.
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Discussion {#pai12673-sec-0020}
==========

We found strong evidence for an association between *TRPA1* polymorphisms and asthma in children at 7--8 years of age in the population‐based ALSPAC birth cohort. Of the six SNPs most significantly associated with asthma in ALSPAC, three showed some evidence of association (and larger effect estimates) with a similar asthma phenotype in the PIAMA birth cohort, whilst none of the six SNPs were associated with asthma at 6 years in Generation R. However, both PIAMA and Generation R were considerably smaller and had a lower prevalence of current asthma, than ALSPAC, and hence lacked statistical power to replicate findings individually. When we meta‐analysed across all three birth cohorts, the pooled effect estimates confirmed associations with asthma overall. Given the *a priori* selection of SNPs, the level of statistical significance for the 'top hits' in the ALSPAC discovery data set, and supportive evidence in PIAMA and following meta‐analysis across all three cohorts, we believe these results may represent a causal influence of the *TRPA1* gene on the risk of active childhood asthma. Other genes in the vicinity of *TRPA1* are unlikely to explain our findings as there is little apparent LD extending between *TRPA1* and other nearby genes (1000 Genomes Phase 1 CEU ([www.1000genomes.org](http://www.1000genomes.org))). To our knowledge, these findings are novel and suggest that TRPA1 may play a role in the development of childhood asthma. Whilst a recent study reported correlations between two *TRPA1* polymorphisms and asthma control in children with asthma [27](#pai12673-bib-0027){ref-type="ref"}, it was underpowered and statistical evidence was weak.

Importance of asthma phenotype {#pai12673-sec-0021}
------------------------------

There is likely to be genetic heterogeneity of asthma phenotypes in childhood [28](#pai12673-bib-0028){ref-type="ref"}, as demonstrated for adult asthma phenotypes [29](#pai12673-bib-0029){ref-type="ref"}. This may partly explain why *TRPA1* was not associated with asthma in the other European studies. A limitation of the GABRIEL asthma GWAS was that the asthma 'ever' phenotype was not directly comparable to the 'current' asthma phenotype used in ALSPAC, PIAMA and Generation R; a doctor diagnosis of asthma 'ever' is likely to comprise many different phenotypes or endotypes which, when analysed together, may lead to dilution of effects of genetic variants [30](#pai12673-bib-0030){ref-type="ref"}. For example, in children, 'asthma ever' may capture early transient childhood wheezing. We confirmed that the effect estimates for the association between *TRPA1* and asthma were smaller in ALSPAC, and especially in PIAMA, when we analysed 'ever' asthma rather than 'current' asthma in these cohorts. Other possible reasons for the lack of association across the other European studies include differences in how cases were selected, which may have contributed to heterogeneity of the asthma phenotype; unreliability of recall of childhood‐onset asthma amongst the adult studies in GABRIEL; and variation in the prevalence of environmental exposures that interact with the gene across different European populations [31](#pai12673-bib-0031){ref-type="ref"}.

Mechanisms {#pai12673-sec-0022}
----------

Given that reactive oxygen species are thought to play an important role in the pathogenesis of airways disease [32](#pai12673-bib-0032){ref-type="ref"}, and the TRPA1 receptor is an important oxidant sensor expressed on sensory neurons innervating the airways [2](#pai12673-bib-0002){ref-type="ref"}, it seems plausible that TRPA1 may play a critical role in asthma pathogenesis. Activation of TRPA1 can, through release of neuropeptides, promote neurogenic airway inflammation [3](#pai12673-bib-0003){ref-type="ref"}, [5](#pai12673-bib-0005){ref-type="ref"}. Conversely, in murine models of airway inflammation induced by allergen, cigarette smoke and paracetamol, deletion or antagonism of TRPA1 has been shown to reduce airway inflammation and hyper‐reactivity [6](#pai12673-bib-0006){ref-type="ref"}, [10](#pai12673-bib-0010){ref-type="ref"}, [33](#pai12673-bib-0033){ref-type="ref"}. However, as neurogenic inflammation has not been demonstrated in human asthma, there are two other mechanisms to consider. First, TRPA1 may also influence airway inflammation non‐neuronally, as confirmed in animals [34](#pai12673-bib-0034){ref-type="ref"}, and recent *in vitro* studies have shown that *TRPA1* is functionally expressed in human lung, including pulmonary epithelial cells [34](#pai12673-bib-0034){ref-type="ref"}, [35](#pai12673-bib-0035){ref-type="ref"}, smooth muscle cells [34](#pai12673-bib-0034){ref-type="ref"} and lung fibroblasts [35](#pai12673-bib-0035){ref-type="ref"}. Second, a neuronal reflex mechanism may be involved, as suggested by experiments in rodents [36](#pai12673-bib-0036){ref-type="ref"}.

The lack of modification of the association between *TRPA1* and asthma by prenatal paracetamol exposure suggests that, even if foetal TRPA1 is activated by exposure to the metabolite of paracetamol [10](#pai12673-bib-0010){ref-type="ref"} *in utero*, this mechanism is unlikely to explain the association between prenatal paracetamol and asthma. The apparent interaction we observed between prenatal paracetamol exposure and *TRPA1* genotype on IgE concentration is intriguing, but may be a chance finding and we cannot offer a mechanistic explanation. We speculate that other prenatal and post‐natal oxidant exposures may be more important than paracetamol as activators of TRPA1, thus contributing to the association we have found between *TRPA1* genotype and childhood asthma.

Conclusions and future work {#pai12673-sec-0023}
===========================

Our findings suggest, for the first time, that TRPA1 may play a role in the development of childhood asthma. In terms of therapeutic implications, these data lend further support to the proposition that TRPA1 antagonists may have promising potential in asthma [4](#pai12673-bib-0004){ref-type="ref"}. It is important that our findings are further replicated in adequately powered studies with comparable asthma phenotypes, and we plan to explore interactions between *TRPA1* and other oxidant exposures such as tobacco smoke and air pollution on childhood respiratory outcomes.
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**Figure S1.** Linkage disequilibrium between 31 child *TRPA1* SNPs in ALSPAC using the Haploview program. Values of r^2^ (×100) are shown.
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Click here for additional data file.
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**Figure S2.** Forest plot showing meta‐analysis of the per‐allele association between *TRPA1* rs959974 and asthma 'ever' across GABRIEL studies\*.
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Click here for additional data file.
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**Figure S3.** Forest plot showing meta‐analysis of the per‐allele association between *TRPA1* rs1384001 and asthma 'ever' across GABRIEL studies.
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Click here for additional data file.
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**Figure S4.** Forest plot showing meta‐analysis of the per‐allele association between *TRPA1* rs4738202 and asthma 'ever' across GABRIEL studies.
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Click here for additional data file.
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**Figure S5.** Forest plot showing meta‐analysis of the per‐allele association between *TRPA1* rs7010969 and asthma 'ever' across GABRIEL studies.
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Click here for additional data file.

###### 

**Figure S6.** Forest plot showing meta‐analysis of the per‐allele association between *TRPA1* rs3735945 and asthma 'ever' across GABRIEL studies.
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Click here for additional data file.

###### 

**Table S1.** Summary of *TRPA1* genotype data, including SNP position, minor allele frequency (MAF) and whether SNP was genotyped or imputed in white ALSPAC children.

**Table S2.** Per‐allele associations between child *TRPA1* SNPs and total IgE (log transformed) at 7.5 years in ALSPAC.
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Click here for additional data file.
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**Appendix S1.** Methods.

###### 

Click here for additional data file.
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